WLWeiwei Li

Weiwei Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Weiwei Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ketone Body Metabolism in Cancer-Associated Fibroblasts and FSTL3 as Prognostic and Therapeutic Determinants of Chemoradiotherapy Response in Cervical Cancer

    by Hua Yang, Litian Ma, Rui Ma, Dong Huang, Weiwei Li, Jianping Li, Yong Zhu, Lichun Wei, Zi Liu

    Background: Concurrent chemoradiotherapy (CCRT) is a cornerstone of treatment for locally advanced cervical cancer, although many patients show a poor response. The tumor microenvironment (TME) is a key determinant of therapeutic resistance and prognosis, with the metabolic reprogramming within specific cellular subsets playing a particularly important role. However, the cellular sources of metabolic heterogeneity in cervical cancer and their clinical implications have yet to be firmly established. Methods: An integrated analysis of single-cell RNA sequencing (scRNA-seq) datasets from eight patients cervical cancer, together with bulk RNA sequencing data retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets, was conducted. Cellular heterogeneity was characterized using the Seurat and Harmony, while metabolic activity was assessed by integrating five algorithms (AUCell, UCell, singscore, ssGSEA, and AddModuleScore). The Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression was used to construct a prognostic model, which was subsequently validated in external cohorts. The functional role of the key gene FSTL3 was examined through both in vitro and in vivo experiments. Results: scRNA-seq analyses identified 10 major cell types within the cervical cancer TME. Among these, cancer-associated fibroblasts (CAFs) showed the greatest enrichment of ketone body metabolism-related gene signatures. CAFs with high enrichment of these signatures exhibited enhanced cell–cell communication and were associated with activation of the AP-1 transcription factor network. Analysis of these CAFs led to the development of a nine-gene prognostic signature (KLF4, SERPINF1, CD74, PRPS2, ERRFI1, FSTL3, SOD2, JUN, and CXCL3). A risk model based on these genes predicted survival in the TCGA training and validation sets and in independent GEO cohorts (disease-free survival in GSE44001 and overall survival in GSE52903). A nomogram combining the risk score with clinical variables showed improved predictive performance compared with either the risk score or clinical variables alone. Knockdown of FSTL3 suppressed tumor growth and enhanced sensitivity to irradiation and cisplatin in both in vitro and in vivo models, supporting its functional role in cervical cancer progression and treatment response. Conclusion: These analyses identify a CAF population enriched in ketone body metabolism-related gene expression that may be associated with cervical cancer progression. In addition to establishing a prognostic model for further evaluation, this study identifies FSTL3 as a potential therapeutic target that warrants further mechanistic and pharmacological investigation.

  • Open Access

    Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer

    by Weiwei Li, Mohan Dong, Shigao Huang, Liu Shi, Hua Yang, Ying Zhang, Jie Gong, Mei Shi, Lichun Wei, Lina Zhao

    The standard of care for locally advanced cervical cancer is concurrent chemoradiotherapy, which is associated with significant toxicity, especially hematologic toxicity. To evaluate the efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during radical chemoradiotherapy for cervical cancer, 40 patients receiving prophylaxis from February 2018 to July 2019 were randomly divided into two arms in a 1:1 ratio. Patients in the study arm (N = 21) received PEG-rhG-CSF, while patients in the control arm (N = 19) received short-acting rhG-CSF. The primary endpoint was the incidence of grade 3–4 neutropenia, and the secondary endpoints were the incidence of febrile neutropenia, chemotherapy delay, and radiotherapy interruption. In addition, dynamic changes in absolute neutrophil count during radical chemoradiotherapy and adverse events were compared between the two groups. There were 0 and 4 cycles of grade 3–4 neutropenia in the PEG-rhG-CSF and rhG-CSF groups, respectively. The incidence of neutropenia of all grades was lower in patients on PEG-rhG-CSF than on rhG-CSF [24.05% (19/79) vs. 56.94% (41/72); p < 0.001]. No patient developed neutropenic fever. The lowest values of neutropenia during concurrent chemoradiotherapy cycles were 2.73 ± 1.02 and 1.91 ± 0.79 × 10 9/ml in the PEG-rhG-CSF and rhG-CSF groups, respectively (p < 0.001). In the PEG-rhG-CSF and rhG-CSF groups, 0 and 8 (11.11%) cycles of chemotherapy were delayed due to neutropenia, respectively (p = 0.01). There was no delay of radiotherapy by more than one week in either group. Prophylactic use of PEG-rhG-CSF during chemoradiotherapy for cervical cancer can effectively prevent neutropenia and associated adverse events. PEG-rhG-CSF may be an effective strategy to provide uninterrupted radical chemoradiotherapy for cervical cancer.